In vivo selection of transplanted hepatocytes by pharmacological inhibition of fumarylacetoacetate hydrolase in wild-type mice

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1981-1987

  Paulk, Nicole K ^a   Wursthorn, Karsten ^b   Haft, Annelise ^a   Pelz, Carl ^a   Clarke, Gregory ^a   Newell, Amy H ^a   Olson, Susan B ^a   Harding, Cary O ^a   Finegold, Milton J ^c   Bateman, Raymond L ^d   Witte, John F ^d   McClard, Ronald ^d   Grompe, Markus ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d REED COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 CARBOXYETHYL)HYDROXYPHOSPHINYL] 3 OXOBUTYRATE; FUMARYLACETOACETASE; HOMOGENTISATE 1,2 DIOXYGENASE; HYDROLASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL SELECTION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; FAH GENE; FEMALE; GENE; GENE EXPRESSION; GENETIC DISORDER; HEPATOCYTE TRANSPLANTATION; HGD GENE; IN VIVO STUDY; LIVER CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SINGLE DRUG DOSE; TREATMENT DURATION; WILD TYPE;

ANIMALIA; MUS;

EID: 84867017075     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.154     Document Type: Article

References (50)

1. Shneider, BL (2002). Pediatric liver transplantation in metabolic disease: clinical decision making. Pediatr Transplant 6: 25-29.
2. Busuttil, RW, Klintmalm, GB, Lake, JR, Miller, CM and Porayko, M (1996). General guidelines for the use of tacrolimus in adult liver transplant patients. Transplantation 61: 845-847.
3. Grompe, M (2001). The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 21: 563-571.
4. Al-Dhalimy, M, Overturf, K, Finegold, M and Grompe, M (2002). Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I. Mol Genet Metab 75: 38-45.
5. Overturf, K, Al-Dhalimy, M, Tanguay, R, Brantly, M, Ou, CN, Finegold, M et al. (1996). Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 12: 266-273.
6. Kvittingen, EA, Rootwelt, H, Brandtzaeg, P, Bergan, A and Berger, R (1993). Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91: 1816-1821.
7. Overturf, K, al-Dhalimy, M, Ou, CN, Finegold, M, Tanguay, R, Lieber, A et al. (1997). Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 8: 513-521.
8. Paulk, NK, Wursthorn, K, Wang, Z, Finegold, MJ, Kay, MA and Grompe, M (2010). Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology 51: 1200-1208.
9. Montini, E, Held, PK, Noll, M, Morcinek, N, Al-Dhalimy, M, Finegold, M et al. (2002). In vivo correction of murine tyrosinemia type I by DNA-mediated transposition. Mol Ther 6: 759-769.
10. Held, PK, Olivares, EC, Aguilar, CP, Finegold, M, Calos, MP and Grompe, M (2005). In vivo correction of murine hereditary tyrosinemia type I by phiC31 integrase-mediated gene delivery. Mol Ther 11: 399-408.
11. Bateman, RL, Ashworth, J, Witte, JF, Baker, LJ, Bhanumoorthy, P, Timm, DE et al. (2007). Slow-onset inhibition of fumarylacetoacetate hydrolase by phosphinate mimics of the tetrahedral intermediate: kinetics, crystal structure and pharmacokinetics. Biochem J 402: 251-260.
12. Bateman, RL, Bhanumoorthy, P, Witte, JF, McClard, RW, Grompe, M and Timm, DE (2001). Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor. J Biol Chem 276: 15284-15291.
13. Manning, K, Al-Dhalimy, M, Finegold, M and Grompe, M (1999). In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I. Proc Natl Acad Sci USA 96: 11928-11933.
14. Grompe, M, Lindstedt, S, al-Dhalimy, M, Kennaway, NG, Papaconstantinou, J, Torres-Ramos, CA et al. (1995). Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nat Genet 10: 453-460.
15. Willenbring, H, Sharma, AD, Vogel, A, Lee, AY, Rothfuss, A, Wang, Z et al. (2008). Loss of p21 permits carcinogenesis from chronically damaged liver and kidney epithelial cells despite unchecked apoptosis. Cancer Cell 14: 59-67.
16. Grompe, M (2006). Principles of therapeutic liver repopulation. J Inherit Metab Dis 29: 421-425.
17. -/- mice. Nat Biotechnol 25: 903-910.
18. Grossman, M, Raper, SE, Kozarsky, K, Stein, EA, Engelhardt, JF, Muller, D et al. (1994). Successful ex vivo gene therapy directed to liver in a patient with familial hypercholesterolaemia. Nat Genet 6: 335-341.
19. Kay, MA and High, K (1999). Gene therapy for the hemophilias. Proc Natl Acad Sci USA 96: 9973-9975.
20. Wang, L, Wang, H, Morizono, H, Bell, P, Jones, D, Lin, J et al. (2012). Sustained correction of OTC defciency in spf(?ash) mice using optimized self-complementary AAV2/8 vectors. Gene Ther 19: 404-410.
21. Fox, IJ, Chowdhury, JR, Kaufman, SS, Goertzen, TC, Chowdhury, NR, Warkentin, PI et al. (1998). Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 338: 1422-1426.
22. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
23. Daya, S and Berns, KI (2008). Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21: 583-593.
24. Allen, KJ, Cheah, DM, Wright, PF, Gazeas, S, Pettigrew-Buck, NE, Deal, YH et al. (2004). Liver cell transplantation leads to repopulation and functional correction in a mouse model of Wilson's disease. J Gastroenterol Hepatol 19: 1283-1290.
25. De Vree, JM, Ottenhoff, R, Bosma, PJ, Smith, AJ, Aten, J and Oude Elferink, RP (2000). Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 119: 1720-1730.
26. Lomas, DA (2006). The selective advantage of alpha1-antitrypsin defciency. Am J Respir Crit Care Med 173: 1072-1077.
27. Tuñón, MJ, Alvarez, M, Culebras, JM and González- Gallego, J (2009). An overview of animal models for investigating the pathogenesis and therapeutic strategies in acute hepatic failure. World J Gastroenterol 15: 3086-3098.
28. Müller, L, Kasper, P and Kaufmann, G (1992). The clastogenic potential in vitro of pyrrolizidine alkaloids employing hepatocyte metabolism. Mutat Res 282: 169-176.
29. Yamanouchi, K, Zhou, H, Roy-Chowdhury, N, Macaluso, F, Liu, L, Yamamoto, T et al. (2009). Hepatic irradiation augments engraftment of donor cells following hepatocyte transplantation. Hepatology 49: 258-267.
30. Sorrentino, BP (2002). Gene therapy to protect haematopoietic cells from cytotoxic cancer drugs. Nat Rev Cancer 2: 431-441.
31. Koç, ON, Reese, JS, Davis, BM, Liu, L, Majczenko, KJ and Gerson, SL (1999). DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1, 3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1, 3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther 10: 1021-1030.
32. Mitchell, C, Mignon, A, Guidotti, JE, Besnard, S, Fabre, M, Duverger, N et al. (2000). Therapeutic liver repopulation in a mouse model of hypercholesterolemia. Hum Mol Genet 9: 1597-1602.
33. Endo, F, Kubo, S, Awata, H, Kiwaki, K, Katoh, H, Kanegae, Y et al. (1997). Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway. J Biol Chem 272: 24426-24432.
34. Grimm, D and Kay, MA (2006). Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 13: 563-575.
35. Czech, MP, Aouadi, M and Tesz, GJ (2011). RNAi-based therapeutic strategies for metabolic disease. Nat Rev Endocrinol 7: 473-484.
36. Holme, E and Lindstedt, S (2000). Nontransplant treatment of tyrosinemia. Clin Liver Dis 4: 805-814.
37. Agliano, A, Martin-Padura, I, Mancuso, P, Marighetti, P, Rabascio, C, Pruneri, G et al. (2008). Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more effcient disease compared to other NOD/scid-related strains. Int J Cancer 123: 2222-2227.
38. Grompe, M, al-Dhalimy, M, Finegold, M, Ou, CN, Burlingame, T, Kennaway, NG et al. (1993). Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7(12A): 2298-2307.
39. Montagutelli, X, Lalouette, A, Coudé, M, Kamoun, P, Forest, M and Guénet, JL (1994). aku, a mutation of the mouse homologous to human alkaptonuria, maps to chromosome 16. Genomics 19: 9-11.
40. Overturf, K, al-Dhalimy, M, Ou, CN, Finegold, M and Grompe, M (1997). Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 151: 1273-1280.
41. Grompe, M, Jones, SN, Loulseged, H and Caskey, CT (1992). Retroviral-mediated gene transfer of human ornithine transcarbamylase into primary hepatocytes of spf and spf-ash mice. Hum Gene Ther 3: 35-44.
42. Ponder, K P, Gupta, S, Leland, F, Darlington, G, Finegold, M, DeMayo, J et al. (1991). Mouse hepatocytes migrate to liver parenchyma and function indefnitely after intrasplenic transplantation. Proc Natl Acad Sci USA 88: 1217-1221.
43. Mitchell, C and Willenbring, H (2008). A reproducible and well-tolerated method for 2/3 partial hepatectomy in mice. Nat Protoc 3: 1167-1170.
44. Eckert, JW, Buerkle, CJ, Major, AM, Finegold, MJ and Brandt, ML (1995). In situ hybridization utilizing a Y chromosome DNA probe. Use as a cell marker for hepatocellular transplantation. Transplantation 59: 109-111.
45. Slocum, RH, and Cummings, JG (1991). Techniques in Diagnostic Human Biochemical Genetics: A Laboratory Manual, Wiley-Liss: New York.
46. Hoffmann, G, Aramaki, S, Blum-Hoffmann, E, Nyhan, WL and Sweetman, L (1989). Quantitative analysis for organic acids in biological samples: batch isolation followed by gas chromatographic-mass spectrometric analysis. Clin Chem 35: 587-595.
47. Irizarry, RA, Hobbs, B, Collin, F, Beazer-Barclay, YD, Antonellis, KJ, Scherf, U et al. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
48. Storey, JD (2002). A direct approach to false discovery rates. J Roy Statis Soc B 64: 479-498.
49. Smyth, GK (2004). Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3: Article3.
50. McCarthy, DJ and Smyth, GK (2009). Testing signifcance relative to a fold-change threshold is a TREAT. Bioinformatics 25: 765-771.